Mitsubishi Tanabe aims high as it eyes shift to new products and markets
This article was originally published in Scrip
Despite falling far short of the goals of its last mid-term business programme, Japan's Mitsubishi Tanabe Pharma (MTP) has unveiled an ambitious new five-year management plan under which it is aiming for group operating profit of ¥100 billion ($1.30 billion) on net sales of ¥500 billion.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.